The Translational Neurogenomics Laboratory is headed by Prof. Dr. Eske Derks. The group currently includes 10 members (2 postdocs, 2 visiting scientists, 2 PhD students and 3 undergraduate students). The Translational Neurogenomics Laboratory has identified genetic risk factors for a range of neuropsychiatric conditions, including substance use disorders, schizophrenia, depression, and obsessive compulsive disorder. Researchers in this group use genetic data to address questions, such as: Which genetic variants in the DNA increase the risk of developing a neuropsychiatric disease? What is the genetic overlap across different psychiatric disorders? What are the downstream molecular consequences underlying statistical genetic associations? Which existing drugs may be repurposed for prevention and treatment of neuropsychiatric diseases?
Group Leader: Professor Eske Derks
- Zachary Gerring, PhD Student
- Inga Schwabe, Visiting Student
- Andries Marees, PhD Student
- Angela Sunley, Honours Student
Spanagel, R., Durstewitz, D., Hansson, A., Heinz, A., Kiefer, F., Kohr, G., Matthaus, F., Nothen, M. M., Noori, H. R., Obermayer, K., Rietschel, M., Schloss, P., Scholz, H., Schumann, G., Smolka, M., Sommer, W., Vengeliene, V., Walter, H., Wurst, W., Zimmermann, U. S., Stringer, S., Smits, Y. & Derks, EM (2013). A systems medicine research approach for studying alcohol addiction. Addiction Biology, 18, 883-896 (5.93).
Stringer, S., Minica, C. C., Verweij, K. J., Mbarek, H., Bernard, M., Derringer, J., . . ., Derks, E.M.* Vink, J. M.* (2016). Genome-wide association study of lifetime cannabis use based on a large meta-analytic sample of 32 330 subjects from the International Cannabis Consortium. Transl Psychiatry, 6, e769.
Stringer, S., Kahn, R. S., de Witte, L. D., Ophoff, R. A., & Derks, E. M. (2014). Genetic liability for schizophrenia predicts risk of immune disorders. Schizophr.Res., 159, 347-352.
Derks EM, Allardyce J, Boks MP, Vermunt JK, Hijman R, Ophoff RA, and GROUP investigators (2012). Kraepelin was right: a latent class analysis of symptom dimensions in patients and controls. Schizophrenia Bulletin, 38, 495-505 (8.61). (27 citations)
Derks EM, Fleischhacker WW, Boter H, Peuskens J, Kahn RS for the EUFEST study group (2010). Antipsychotic drug treatment in first-episode psychosis: Should patients be switched to a different antipsychotic drug after two, four, or six weeks of non-response? Journal of Clinical Psychopharmacology, 30(2),176-180
- What causes overlap between mental health disorders?
- What makes one at risk for having a mental health disorder? Investigating the regulatory role of genetic variants
If you wish to apply for QIMR Berghofer's student program,
click here for more information.